Pharmacological HIF activation protects against diet-induced obesity, glucose intolerance, and skeletal dysfunction by exerting dual beneficial effects on energy metabolism and bone
Roger Valle-Tenney(KU Leuven), Christa Maes(KU Leuven), Elena Nefyodova(KU Leuven), Ruben Cardoen(KU Leuven), Nicolas Peredo(KU Leuven), Tom Dehaemers(KU Leuven), Roman Vangoitsenhoven(KU Leuven), Roland Chapurlat(Lyon 1 Université), Bart Van der Schueren(KU Leuven), Karen De Samblancx(KU Leuven), Chantal Mathieu(KU Leuven), Delphine Farlay(Lyon 1 Université)
Cited by 2
Related Papers
Osteoblast Precursors, but Not Mature Osteoblasts, Move into Developing and Fractured Bones along with Invading Blood Vessels
|Developmental Cell|2010|930
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
|Mechanisms of Development|2002|456
Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF
|Journal of Bone and Mineral Research|2009|409
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts
|Journal of Clinical Investigation|2006|331
VEGF: A modifier of the del22q11 (DiGeorge) syndrome?
|Nature Medicine|2003|313